Literature DB >> 9580601

Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone.

G E Duncan1, D J Knapp, S W Carson, G R Breese.   

Abstract

Hypersecretion of cortisol occurs in numerous patients with major depression and normalizes with clinical recovery during the course of chronic antidepressant treatment. These clinical data suggest that investigation of the effects of antidepressant treatments on the regulation of the brain-pituitary-adrenal axis may assist in elucidating the therapeutic basis of antidepressant actions. In the present investigation, both swim stress and acute fluoxetine challenge increased release of corticosterone and progesterone to reflect an activation of the brain pituitary-adrenal axis. The effects of chronic antidepressant treatment (21 days) on corticosterone and progesterone secretion induced by these challenges were investigated. Chronic fluoxetine treatment (5 mg/kg/day) completely blocked the increased secretion of corticosterone and progesterone in response to the acute fluoxetine challenge. Chronic treatment with desipramine, imipramine or amytriptyline (15 mg/kg/day) also markedly attenuated fluoxetine-induced corticosterone and progesterone secretion. However, chronic treatment with the monoamine oxidase inhibitors, phenelzine (5 mg/kg) and tranylcypromine (5 mg/kg), did not affect this hormonal response to acute fluoxetine challenge. Plasma levels of fluoxetine after acute challenge were not significantly different for the various chronic antidepressant treatment conditions from the chronic saline controls; therefore, an increase in the metabolism of fluoxetine can not explain the antagonism of the fluoxetine-induced hormonal response after chronic antidepressant treatment. In contrast to the effects of selected antidepressants on acute fluoxetine-induced steroid release, chronic treatment with imipramine (20 mg/kg/day), fluoxetine (5 mg/kg/day) or phenelzine (5 mg/kg) did not significantly alter this swim stress-induced corticosterone or progesterone secretion. Because chronic fluoxetine and tricyclic antidepressant drugs blocked the acute action of fluoxetine to increase adrenal cortical secretion, but did not alter swim stress-induced secretion of these steroids, we propose that distinct neurochemical mechanisms control fluoxetine and swim stress-induced steroid release. We speculate that the substantial adaptive response to those chronic antidepressant treatments, which minimize the effect of acute fluoxetine challenge to increase in corticosterone and progesterone secretion, may be relevant to the therapeutic actions of these drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580601      PMCID: PMC3025615     

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  49 in total

1.  Behavioural despair in rats: a new model sensitive to antidepressant treatments.

Authors:  R D Porsolt; G Anton; N Blavet; M Jalfre
Journal:  Eur J Pharmacol       Date:  1978-02-15       Impact factor: 4.432

2.  Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function.

Authors:  A W Meikle; F H Tyler
Journal:  Am J Med       Date:  1977-08       Impact factor: 4.965

3.  Rapid down regulation of beta adrenergic receptors by combining antidepressant drugs with forced swim: a model of antidepressant-induced neural adaptation.

Authors:  G E Duncan; I A Paul; T K Harden; R A Mueller; W E Stumpf; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1985-08       Impact factor: 4.030

4.  Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor.

Authors:  M D Majewska; N L Harrison; R D Schwartz; J L Barker; S M Paul
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

5.  Examination of the relationship between the uptake system for 5-hydroxytryptamine and the high-affinity [3H]imipramine binding site--I. Inhibition by drugs.

Authors:  M D Wood; A M Broadhurst; M G Wyllie
Journal:  Neuropharmacology       Date:  1986-05       Impact factor: 5.250

6.  Premenstrual depression, cortisol and oestradiol treatment.

Authors:  J L Crammer
Journal:  Psychol Med       Date:  1986-05       Impact factor: 7.723

7.  A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility.

Authors:  B J Carroll; M Feinberg; J F Greden; J Tarika; A A Albala; R F Haskett; N M James; Z Kronfol; N Lohr; M Steiner; J P de Vigne; E Young
Journal:  Arch Gen Psychiatry       Date:  1981-01

8.  Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression.

Authors:  A Randrup; C Braestrup
Journal:  Psychopharmacology (Berl)       Date:  1977-08-16       Impact factor: 4.530

9.  The pharmacologic profile of fluoxetine.

Authors:  P Stark; R W Fuller; D T Wong
Journal:  J Clin Psychiatry       Date:  1985-03       Impact factor: 4.384

10.  Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.

Authors:  C B Nemeroff; E Widerlöv; G Bissette; H Walléus; I Karlsson; K Eklund; C D Kilts; P T Loosen; W Vale
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

View more
  13 in total

1.  Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes.

Authors:  Michael W Otto; R Kathryn McHugh; Kathleen M Kantak
Journal:  Clin Psychol (New York)       Date:  2010-06-08

2.  Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise.

Authors:  Benjamin N Greenwood; Paul V Strong; Leah Brooks; Monika Fleshner
Journal:  Psychopharmacology (Berl)       Date:  2008-05-03       Impact factor: 4.530

3.  Nerve growth factor (NGF) has novel antidepressant-like properties in rats.

Authors:  David H Overstreet; Kellie Fredericks; Darin Knapp; George Breese; John McMichael
Journal:  Pharmacol Biochem Behav       Date:  2009-11-27       Impact factor: 3.533

4.  Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain.

Authors:  Antonio Ortega-Alvaro; Ignacio Acebes; Gonzalo Saracíbar; Enrique Echevarría; Luis Casis; Juan Antonio Micó
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

5.  Possible involvement of the JAK/STAT signaling pathway in N-acetylcysteine-mediated antidepressant-like effects.

Authors:  Marwa M Al-Samhari; Nouf M Al-Rasheed; Salim Al-Rejaie; Nawal M Al-Rasheed; Iman H Hasan; Ayman M Mahmoud; Nduna Dzimiri
Journal:  Exp Biol Med (Maywood)       Date:  2015-12-06

6.  Activation of mGluR2/3 following stress hormone exposure restores sensitivity to alcohol in rats.

Authors:  Anel A Jaramillo; Patrick A Randall; Suzanne Frisbee; Kristen R Fisher; Joyce Besheer
Journal:  Alcohol       Date:  2015-06-19       Impact factor: 2.405

7.  Synergistic anticataleptic effect of imipramine and nicotine in a rotenone-induced rat model.

Authors:  Ilya D Ionov; Irina I Pushinskaya; Nicholas P Gorev; Larissa A Shpilevaya
Journal:  Psychopharmacology (Berl)       Date:  2019-05-08       Impact factor: 4.415

8.  Temporal variability of glucocorticoid receptor activity is functionally important for the therapeutic action of fluoxetine in the hippocampus.

Authors:  M-S Lee; Y-H Kim; W-S Park; O-K Park; S-H Kwon; K S Hong; H Rhim; I Shim; K Morita; D L Wong; P D Patel; D M Lyons; A F Schatzberg; S Her
Journal:  Mol Psychiatry       Date:  2014-10-21       Impact factor: 15.992

9.  Stress-induced increases in progesterone and cortisol in naturally cycling women.

Authors:  Alexandra Ycaza Herrera; Shawn E Nielsen; Mara Mather
Journal:  Neurobiol Stress       Date:  2016-02-11

10.  Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants.

Authors:  Laura Musazzi; Marco Milanese; Pasqualina Farisello; Simona Zappettini; Daniela Tardito; Valentina S Barbiero; Tiziana Bonifacino; Alessandra Mallei; Pietro Baldelli; Giorgio Racagni; Maurizio Raiteri; Fabio Benfenati; Giambattista Bonanno; Maurizio Popoli
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.